ALSEN Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.…
Industry Peers
BiotechnologyKey Statistics
About Sensorion (EPA: ALSEN)
›
Sensorion (EPA: ALSEN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 66 employees.
The shares were at 7.624 EUR on 19 November 2026, down 55.0% over 52 weeks. Its 52-week range is 5.249 EUR to 40.40 EUR: the price is 81.1% below the high and 45.2% above the low.
Its market capitalisation is 78.58M EUR.
Sensorion reports return on equity of -66.2% and revenue up 14.7% year over year.
It holds more cash than debt, a net cash position of 85.30M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.